课题基金 / 基金详情

TEMPO-2 - Multicentre, prospective randomized open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with low dose Tenecteplase (TNK-tPA) versus standard of care in the prevention of disability at 3 months in minor ischemic stroke with prov

TEMPO-2 - Multicentre, prospective randomized open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with low dose Tenecteplase (TNK-tPA) versus standard of care in the prevention of disability at 3 months in minor ischemic stroke with prov
TEMPO-2 - 多中心、前瞻性随机开放标签、盲终点 (PROBE) 对照试验,比较低剂量替奈普酶 (TNK-tPA) 溶栓与标准护理预防轻微缺血性卒中 3 个月残疾的效果,并经证实
批准号:
351760
负责人:
Coutts Shelagh B
金额:
$7.29万
依托单位:
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2016
资助国家:
加拿大
项目状态:
已结题
起止时间:
2016-04-01 至 2017-04-01

项目摘要

项目成果

Coutts Shelagh B的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Most minor strokes are due to lack of blood getting to a part of the brain. When this occurs, patients get sudden loss of function in that region of the brain. This might mean inability to move a limb or inability to speak. In the luckiest case, this dy
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TEMPO-2 - A randomized controlled trial of TNK-tPA versus standard of care for minor ischemic stroke with proven occlusion.
  • 批准号:
    368184
  • 项目类别:
    Operating Grants
  • 资助金额:
    $145.18万
  • 财政年份:
    2017
  • 负责人:
    Coutts Shelagh B
  • 依托单位:
TEMPO-2 - A randomized controlled trial of TNK-tPA versus standard of care for minor ischemic stroke with proven occlusion
  • 批准号:
    366546
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2016
  • 负责人:
    Coutts Shelagh B
  • 依托单位:
Diagnosis Of Uncertain-origin Benign Transient neurological symptoms. (DOUBT)
  • 批准号:
    224084
  • 项目类别:
    Operating Grants
  • 资助金额:
    $43.34万
  • 财政年份:
    2011
  • 负责人:
    Coutts Shelagh B
  • 依托单位:
Diagnosis Of Uncertain-origin Benign Transient neurological symptoms. (DOUBT)
  • 批准号:
    220811
  • 项目类别:
    Operating Grants
  • 资助金额:
    $6.82万
  • 财政年份:
    2010
  • 负责人:
    Coutts Shelagh B
  • 依托单位:
海外基金